BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//LifeSci Events - ECPv6.15.11//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:LifeSci Events
X-ORIGINAL-URL:https://lifescievents.com
X-WR-CALDESC:Events for LifeSci Events
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Chicago
BEGIN:DAYLIGHT
TZOFFSETFROM:-0600
TZOFFSETTO:-0500
TZNAME:CDT
DTSTART:20250309T080000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0500
TZOFFSETTO:-0600
TZNAME:CST
DTSTART:20251102T070000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0600
TZOFFSETTO:-0500
TZNAME:CDT
DTSTART:20260308T080000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0500
TZOFFSETTO:-0600
TZNAME:CST
DTSTART:20261101T070000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0600
TZOFFSETTO:-0500
TZNAME:CDT
DTSTART:20270314T080000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0500
TZOFFSETTO:-0600
TZNAME:CST
DTSTART:20271107T070000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/Chicago:20260601T063000
DTEND;TZID=America/Chicago:20260601T073000
DTSTAMP:20260429T082640
CREATED:20260409T135333Z
LAST-MODIFIED:20260423T141613Z
UID:2982-1780295400-1780299000@lifescievents.com
SUMMARY:Corbus Pharmaceuticals - In-Person and Virtual Investor Event to Discuss Updated CRB–701 Monotherapy Data in HNSCC
DESCRIPTION:Join Corbus Pharmaceuticals for an in-person and virtual investor event featuring key opinion leaders (KOLs) Ari Rosenberg\, MD (UChicago Medicine)\, Glenn Hanna\, MD (Dana-Farber Cancer Institute)\, and Cesar Augusto Perez Batista\, MD (Sarah Cannon Research Institute)\, hosted by Yuval Cohen\, Corbus CEO to discuss updated data from its Phase 1/2 clinical study of CRB-701 in over 75 participants with head and neck squamous cell carcinoma (HNSCC). Data will include clinical response durability as well as HNSCC patient subgroup analysis. These data will be presented as a poster at the American Society of Clinical Oncology (ASCO) Annual Meeting 2026\, to be held May 29 – June 2\, 2026 in Chicago\, IL. \nThe ongoing three-part Phase 1/2 study has evaluated the safety\, pharmacokinetics and efficacy of CRB-701 in over 317 participants with advanced solid tumors associated with high Nectin-4 expression. CRB-701 is a next-generation antibody-drug-conjugate (ADC) targeting Nectin-4\, that contains a site-specific\, cleavable linker and a homogenous drug antibody ratio of 2\, using MMAE as the payload. \nCorbus recently announced broad alignment with the FDA on the registration path for CRB-701 in HNSCC. \nA live question and answer session will follow the formal presentation and discussion. Watch the webcast by clicking this link and logging in with the email address you used to register: https://lifescievents.com/event/rk0t83lp/.
URL:https://lifescievents.com/event/rk0t83lp/
LOCATION:Marriott Marquis Chicago & Live Webcast\, Marriott Marquis Chicago\, 2121 S Prairie Ave\, Chicago\, IL 60616
ATTACH;FMTTYPE=image/png:https://lifescievents.com/wp-content/uploads/2026/04/Corbus-Banner.png
END:VEVENT
END:VCALENDAR